Biothera Pharmaceuticals Inc. is a mid clinical-stage biotechnology company advancing Imprime PGG, a first-in-class, systemically administered beta glucan PAMP (pathogen associated molecular pattern). Imprime PGG acts as an immunological “ignition switch,” triggering a robust, coordinated immune response to enhance the anti-tumor effects of checkpoint inhibitors (PD-1, PD-L1 antibodies), anti-angiogenic antibodies (e.g., Avastin®), and tumor-targeting monoclonal antibodies (e.g., Erbitux®). Imprime PGG is the most advanced PAMP in immune-oncology, with a strong safety profile in 400+ patients and established proof of concept in single arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer (mCRC), and chronic lymphocytic leukemia (CLL). Imprime PGG has broad intellectual property protections, with more than 100 issued and pending patients in the US and internationally. Biothera Pharmaceuticals is a subsidiary of Biothera Holding Corp., a privately held company.
Company Growth (employees)
Eagan, US
Size (employees)
72 (est)-2%
Biothera was founded in 1997 and is headquartered in Eagan, US

Key People/Management at Biothera

Richard Mueller

Richard Mueller

William Gacki

William Gacki

Steven Karel

Steven Karel

Myra Patchen

Myra Patchen

Daniel Conners

Daniel Conners

Founder, President & Chairman

Biothera Office Locations

Biothera has an office in Eagan
Eagan, US (HQ)
3388 Mike Collins Dr

Biothera Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$5.1 m

Latest funding size

$1.6 m

Time since last funding

about 3 years
Biothera's latest funding round in December 2014 was reported to be $1.6 m. In total, Biothera has raised $5.1 m

Biothera's Web-traffic and Trends

Biothera Online and Social Media Presence

Biothera Company Life and Culture

You may also be interested in